Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and Cancer of Pancreas

lapatinib has been researched along with Cancer of Pancreas in 22 studies

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (9.09)29.6817
2010's14 (63.64)24.3611
2020's6 (27.27)2.80

Authors

AuthorsStudies
Hiramoto, M; Hirota, A; Kazama, H; Miyazaki, M; Miyazawa, K; Ogawa, M; Ota, K; Suzuki, S; Takano, N1
Hassan, G; Seno, A; Seno, M; Zahra, MH1
Cloyd, JM; Du, S; Mao, Y; Pawlik, TM; Xiao, Y; Xu, G; Zhang, B1
Li, F; Ma, L; Niu, Y; Yan, C; Zhao, W1
Che, B; Chen, L; Du, X; Du, Y; Hao, L; Liu, X; Lu, H; Shao, J; Wang, K; Xiang, M; Xiao, H; Yu, Y; Yuan, R; Zhang, S; Zhang, W; Zhou, W1
Beijnen, JH; Bernards, R; Huijberts, SCFA; Huitema, ADR; Marchetti, S; Monkhorst, K; Opdam, FL; Pulleman, S; Rosing, H; Schellens, JHM; Steeghs, N; Thijssen, B; van Brummelen, EMJ; van Geel, RMJM1
Adair, SJ; Bauer, TW; Borgman, CA; Chopivsky, ME; Cowan, CR; Gilmer, TM; Lindberg, JM; Lowrey, BT; Newhook, TE; Parsons, JT; Stelow, EB; Stokes, JB; Walters, DM1
Amano, R; Hirakawa, K; Hirata, K; Kimura, K; Komoto, M; Murata, A; Nakata, B1
Anderson, E; Bahary, N; Charpentier, K; Clark, A; Kennedy, T; Lopez, CD; McNulty, B; Miner, T; Safran, H; Schumacher, A; Shipley, J; Sio, T; Sun, W; Vakharia, J; Whiting, S1
Annunziato, S; Benedicenti, F; Brasca, S; Calabria, A; Gallina, P; Montini, E; Naldini, L; Ranzani, M1
Mazo, A; Pérez-Torras, S; Urtasun, N; Vidal-Pla, A1
Gabrielson, A; He, AR; Hwang, JJ; Ley, L; Marshall, JL; Pishvaian, MJ; Weiner, LM; Wu, Z; Zhuang, T1
Cheng, M; Conteh, AM; Craven, KE; Gore, J; Imasuen-Williams, IE; Korc, M1
Amano, R; Hirakawa, K; Kawajiri, H; Komoto, M; Nakata, B; Nishii, T; Shinto, O; Yamada, N; Yashiro, M1
Baerman, KM; Calvo, BF; Cox, AD; Kimple, RJ; Sartor, CI; Shields, JM; Tepper, JE; Vaseva, AV1
Oberstein, PE; Saif, MW1
Azria, D; Bascoul-Mollevi, C; Campigna, E; Chardès, T; Coelho, M; Gaborit, N; Larbouret, C; Mach, JP; Pèlegrin, A; Robert, B1
Ramfidis, VS; Saif, MW; Strimpakos, AS; Syrigos, KN1
Drebin, JA; Pippin, JA; Singla, S1
Clynes, M; Corkery, B; Crown, J; Kennedy, S; Larkin, A; O'Donovan, N; O'Driscoll, L; Walsh, N1
Burtness, B1
Dipetrillo, T; Evans, D; Gutman, N; Joseph, P; Kennedy, T; McNulty, B; Millis, R; Miner, T; Plette, A; Resnick, M; Safran, H; Sears, D1

Reviews

1 review(s) available for lapatinib and Cancer of Pancreas

ArticleYear
Her signaling in pancreatic cancer.
    Expert opinion on biological therapy, 2007, Volume: 7, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Epidermal Growth Factor; Erlotinib Hydrochloride; Gemcitabine; Humans; Lapatinib; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome

2007

Trials

4 trial(s) available for lapatinib and Cancer of Pancreas

ArticleYear
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
    Cancer chemotherapy and pharmacology, 2020, Volume: 85, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Lapatinib; Male; Middle Aged; Mutation; Pancreatic Neoplasms; Pharmacogenetics; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Treatment Outcome

2020
Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study.
    American journal of clinical oncology, 2011, Volume: 34, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure

2011
Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome

2015
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
    American journal of clinical oncology, 2008, Volume: 31, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Quinazolines; Survival Analysis

2008

Other Studies

17 other study(ies) available for lapatinib and Cancer of Pancreas

ArticleYear
Lysosome‑targeted drug combination induces multiple organelle dysfunctions and non‑canonical death in pancreatic cancer cells.
    Oncology reports, 2022, Volume: 47, Issue:2

    Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Stress; Fingolimod Hydrochloride; Humans; Hydroxychloroquine; Lapatinib; Lysosomes; Pancreatic Neoplasms; Sphingosine 1 Phosphate Receptor Modulators

2022
The significance of ErbB2/3 in the conversion of induced pluripotent stem cells into cancer stem cells.
    Scientific reports, 2022, 02-17, Volume: 12, Issue:1

    Topics: Acrylamides; Adenine; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Self Renewal; Culture Media, Conditioned; Gene Expression Regulation, Neoplastic; Humans; Induced Pluripotent Stem Cells; Lapatinib; MAP Kinase Signaling System; Neoplastic Stem Cells; Pancreatic Neoplasms; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction

2022
Gene signature and connectivity mapping to assist with drug prediction for pancreatic ductal adenocarcinoma.
    Surgical oncology, 2022, Volume: 44

    Topics: Aurora Kinase A; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genome-Wide Association Study; Humans; Lapatinib; Pancreatic Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); RNA; Roscovitine; Serine; Threonine; Trypsin

2022
System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma.
    Journal of translational medicine, 2022, 10-05, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Biomarkers, Tumor; DNA-Binding Proteins; Epothilones; Gene Expression Regulation, Neoplastic; Humans; Interleukin-18; Lapatinib; Pancreatic Neoplasms; Pore Forming Cytotoxic Proteins; Prognosis; Pyroptosis

2022
SLC35F2-SYVN1-TRIM59 axis critically regulates ferroptosis of pancreatic cancer cells by inhibiting endogenous p53.
    Oncogene, 2023, Volume: 42, Issue:44

    Topics: Cell Line, Tumor; Ferroptosis; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Lapatinib; Membrane Transport Proteins; Pancreatic Neoplasms; Tripartite Motif Proteins; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases

2023
Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.
    Neoplasia (New York, N.Y.), 2013, Volume: 15, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Humans; Lapatinib; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Signal Transduction

2013
In vitro effects of lapatinib with gemcitabine for pancreatic cancer cells.
    Hepato-gastroenterology, 2013, Volume: 60, Issue:126

    Topics: Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Lapatinib; Pancreatic Neoplasms; Quinazolines; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins

2013
Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2014, Volume: 22, Issue:12

    Topics: Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Genetic Vectors; Humans; Lapatinib; Lentivirus; Molecular Targeted Therapy; Mutagenesis, Insertional; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Prognosis; Protein Kinase Inhibitors; Quinazolines

2014
Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors.
    BMC cancer, 2015, Apr-04, Volume: 15

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lapatinib; Neoplastic Stem Cells; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Spheroids, Cellular; Tumor Cells, Cultured

2015
Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model.
    Cancer letters, 2016, 08-28, Volume: 379, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Movement; Cyclin-Dependent Kinase Inhibitor p16; ErbB Receptors; Female; Gene Expression Profiling; Genes, Retinoblastoma; Genetic Predisposition to Disease; Humans; Lapatinib; Lymphangiogenesis; Male; Mice, Transgenic; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Phenotype; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyrazoles; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta

2016
In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer.
    Cancer science, 2010, Volume: 101, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Combinations; Female; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Oxonic Acid; Pancreatic Neoplasms; Quinazolines; Tegafur; Xenograft Model Antitumor Assays

2010
Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Feb-01, Volume: 16, Issue:3

    Topics: Animals; Cell Line, Tumor; ErbB Receptors; Female; Genes, ras; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mutation; Nelfinavir; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, ErbB-2; Signal Transduction; Xenograft Model Antitumor Assays

2010
First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
    JOP : Journal of the pancreas, 2011, Mar-09, Volume: 12, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Lapatinib; Medicine, Chinese Traditional; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome

2011
In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
    Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:2

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Phosphorylation; Protein Multimerization; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays

2012
Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?
    JOP : Journal of the pancreas, 2012, Jul-10, Volume: 13, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Lapatinib; Leucovorin; Oligodeoxyribonucleotides; Organoplatinum Compounds; Pancreatic Neoplasms; Quinazolines; Thionucleotides

2012
Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.
    Oncology reports, 2012, Volume: 28, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Synergism; ErbB Receptors; Fluorouracil; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Survivin

2012
EGFR and HER2 inhibition in pancreatic cancer.
    Investigational new drugs, 2013, Volume: 31, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Humans; Lapatinib; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2

2013